Holen Sie sich die Stockscreener-App
58.30
2.53%
1.44
Handel nachbörslich:
57.00
-1.30
-2.23%
Schlusskurs vom Vortag:
$56.86
Offen:
$56.94
24-Stunden-Volumen:
2.69M
Relative Volume:
1.17
Marktkapitalisierung:
$11.19B
Einnahmen:
$2.95B
Nettoeinkommen (Verlust:
$523.88M
KGV:
21.67
EPS:
2.69
Netto-Cashflow:
$620.18M
1W Leistung:
-3.91%
1M Leistung:
+0.34%
6M Leistung:
-9.50%
1J Leistung:
-35.92%
1-Tages-Spanne:
$56.94
$58.62
1-Wochen-Bereich:
$56.36
$61.00
52-Wochen-Spanne:
$52.93
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Vergleichen Sie BMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
58.30 | 10.92B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Yahoo Finance
BC consulted U.S. Batten disease experts who had links to drug company - Vancouver Sun
Solid Earnings Reflect BioMarin Pharmaceutical's (NASDAQ:BMRN) Strength As A Business - Yahoo Finance
Can Traders Expect Breakout From BioMarin Pharmaceutical Inc. This WeekJuly 2025 Setups & Stock Timing and Entry Methods - beatles.ru
BioMarin Announces Resignation of Chief Accounting Officer - The Globe and Mail
Skeletal Dysplasia Market Growth Analysis 2025-2030 - GlobeNewswire
Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Leerink Partners Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $105 - Insider Monkey
Refocused, deal-hungry drugmaker BioMarin pushes toward $4 billion revenue target - The Business Journals
Phenylketonuria Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | PTC Therapeutics, Homology Medicine, Synlogic, BioMarin Pharma - Barchart.com
The Top 12 Companies Hiring in Biopharma Now - BioSpace
Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Positive Earnings Growth Hasn't Been Enough to Get BioMarin Pharmaceutical (NASDAQ:BMRN) Shareholders a Favorable Return Over the Last Five Years - 富途牛牛
BioMarin Pharmaceutical Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2025 Earnings Call Transcript - Insider Monkey
BioMarin Pharmaceutical (BMRN) Receives a Buy from Stifel Nicolaus - The Globe and Mail
Biomarin Pharmaceutical shares rise 2.68% premarket after UBS raised its price target to $114. - AInvest
BioMarin Pharmaceutical Inc. Reports Strong Q2 2025 Results - The Globe and Mail
BioMarin’s Earnings Call: Growth Amid Challenges - TipRanks
BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401 (NASDAQ:BMRN) - Seeking Alpha
Research Alert: CFRA Keeps Buy View On Shares Of Biomarin Pharmaceutical Inc. - 富途牛牛
BIOMARIN PHARMACEUTICAL INC SEC 10-Q Report - TradingView
BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030 - inkl
BioMarin stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com
BMRN Makes Bullish Cross Above Critical Moving Average - Nasdaq
BioMarin touts promising early result for potential Voxzogo successor - Fierce Pharma
UBS Adjusts Price Target on BioMarin Pharmaceutical to $114 From $113, Maintains Buy Rating - MarketScreener
BioMarin Axes Pre-Clinical PKU Drug, Citing Underwhelming Immunogenicity - BioSpace
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View - Yahoo Finance
Morgan Stanley Raises Price Target on BioMarin Pharmaceutical to $104 From $96, Keeps Overweight Rating - MarketScreener
BioMarin raises 2025 full-year guidance with $3.125B revenue target and advances BMN 333 - MSN
BioMarin: Q2 Earnings Snapshot - New Haven Register
BioMarin Pharmaceutical Inc (BMRN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
BioMarin’s Earnings Beat Forecasts And Hike Guidance For 2025 - Finimize
BioMarin Pharmaceutical Q2 2025 Earnings Call Transcript - MarketBeat
BioMarin (BMRN) Q2 Revenue Jumps 16% - The Motley Fool
BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Earnings call transcript: Biomarin beats Q2 2025 estimates, stock rises By Investing.com - Investing.com Canada
Earnings call transcript: Biomarin beats Q2 2025 estimates, stock rises - Investing.com
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
BioMarin Pharmaceutical Reports Strong Q2 EarningsNews and Statistics - IndexBox
Biomarin Pharmaceutical Inc. Bottom Line Rises In Q2 - Nasdaq
BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Strong Q2 Numbers, Stock Soars - TradingView
BioMarin Pharmaceutical Q2 Non-GAAP EPS, Revenue Increase; Shares Rise After Hours - MarketScreener
BioMarin Pharma Q2 revenue beats estimates - MarketScreener
Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Reports Q2 Revenue $825.0M, vs. FactSet Est of $761.7M - MarketScreener
Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Posts Q2 Adjusted EPS $1.44 per Share, vs. FactSet Est of $0.82 - MarketScreener
BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS - PR Newswire
What makes BioMarin Pharmaceutical Inc. stock price move sharplyGet real-time alerts on top-performing stocks - Jammu Links News
How does BioMarin Pharmaceutical Inc. compare to its industry peersBuild a portfolio that grows with the market - Jammu Links News
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):